Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides
Objective: Patients included in MAINRITSAN2 trial received either an individually tailored or a fixed-schedule therapy with rituximab as maintenance treatment of antineutrophil cytoplasm antibody associated vasculitides. The aim of this study was to compare the real-world costs of both arms. Meth...
        Saved in:
      
    
          | Main Authors: | Ana Belén Guisado-Gil, Marina Muñoz-Burgos, Ana Ortega-Eslava, Francisco Javier García-Hernández, Bernardo Santos-Ramos | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | Elsevier
    
        2020-03-01 | 
| Series: | Farmacia Hospitalaria | 
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/11287.pdf | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody associated vasculitis: A single-center prospective observational study        
                          
 by: Ekbote Gayatri, et al.
 Published: (2019-01-01)
- 
                
                    Clinical profile and outcome of antineutrophil cytoplasmic antibody-associated vasculitis: A retrospective observational study from South India        
                          
 by: Sham Santhanam, et al.
 Published: (2022-01-01)
- 
                
                    Anti-neutrophil cytoplasmic autoantibodies associated vasculitis – Clinical profile and outcomes        
                          
 by: Kavya Devi Nunna, et al.
 Published: (2018-01-01)
- 
                
                    Clinical value of antineutrophil cytoplasmic antibody positive expression in children with lupus nephritis        
                          
 by: Jing Wang, et al.
 Published: (2024-11-01)
- 
                
                    Antineutrophil cytoplasmic antibody-associated vasculitis in a patient with diffuse scleroderma        
                          
 by: B N Shiva Prasad, et al.
 Published: (2021-01-01)
 
       